Open, Single arm intervention, feasibility study
The aims of the proposed feasibility study are to assess whether a low-energy meal replacement plan (MRP) in patients with HFpEF and T2D: 1\. Is acceptable to an older, co-morbid, multi-ethnic population The secondary objectives are to assess whether a low-energy MRP in patients with HFpEF and T2D may be: 1. associated with improved symptoms 2. likely to lead to favourable cardiovascular reverse remodelling 3. likely to improve functional capacity and quality of life 4. associated with favourable reductions in cardiovascular biomarkers 5. associated with increased physical activity 6. associated with favourable cardiovascular outcomes All patients will undergo the following assessments at baseline, 12-weeks and 12 months (following MRP): 1. Anthropometry: height, weight, BMI. 2. Haemodynamics: resting heart rate and blood pressure. 3. 6-minute walk test +/- cardiopulmonary exercise test (if able to perform) 4. CMR: contrast enhanced, stress perfusion CMR 5. MLWHFQ 6. WHODAS 2.0 (12-item version) 7. Fasting blood test: full blood count, urea and electrolytes, HbA1c, fasting glucose, BNP, high-sensitivity troponin I, insulin and C-peptide. Plasma (≈35mL) will be stored for future biomarker analysis including metabolomics. 8. Urinalysis for proteinuria and urine protein/creatinine ratio. 9. Body composition; dual-energy X-ray absorptiometry (DEXA) scanning. 12\. At the end of the 12-week intervention, participants will be invited to a semi-structured interview to explore qualitative aspects of the study to guide future trial design. 13\. At 12 months attendance at cardiac rehabilitation will be reviewed. The MRP provided by Cambridge Weight Plan® contains \~810 kcal/day (30% protein, 50% carbohydrate, 20% fat). The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
3
Low energy meal replacement plan (12 weeks)
Cardiovascular Research Centre (Glenfield Hospital)
Leicester, Leicestershire, United Kingdom
Recruitment and retention rates
The number of people approached, recruited and retained
Time frame: 16 weeks
Differences in 6 minute walk test pre- and post intervention
Meters walked within 6 minutes
Time frame: 12 weeks
Differences in cardiopulmonary exercise test (peak VO2) pre- and post intervention
exercise test on a static bike using minute by minute ventilatory gas analysis
Time frame: 12 weeks
Differences in LV remodelling (indexed LV mass) pre- and post intervention
CMR measures of cardiac geometry
Time frame: 12 weeks
Differences in LV function pre- and post intervention
CMR measures of cardiac function
Time frame: 12 weeks
Differences in E/A ratio pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in E (cm/s) pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in MV deceleration time (ms) pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in A (cm/s) pre- and post intervention
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Standard clinical echocardiography
Time frame: 12 weeks
Differences in Septal e' pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in Lateral e' pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in Septal E/e' pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in Lateral E/e' pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in Average E/e' pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in LA volume indexed pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in TR jet velocity (m/s) pre- and post intervention
Standard clinical echocardiography
Time frame: 12 weeks
Differences in BMI pre- and post intervention
Weighing scales and stadiometer measurement (Kg/m2)
Time frame: 12 weeks
Differences in Bone Mineral Density (g/cm2) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Differences in Total Fat mass (g) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Differences in Total tissue fat (%) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Differences in visceral adipose tissue mass (g) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Differences in visceral adipose tissue volume (cm3) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Differences in Total lean body mass (g) pre- and post intervention
DEXA scan
Time frame: 12 weeks
Difference in World Health Organisation Disability Schedule (WHODAS 2.0) pre- and post intervention
Scale 0 - 48 with lower scores indicating better outcome
Time frame: 12 weeks
Difference in Medical Research Council Dyspnoea Scale pre- and post intervention
scale 1 - 5 with lower scores indicating better outcome
Time frame: 12 weeks
Difference in Minnesota Living with heart Failure Questionnaire pre- and post intervention
Scale 0 - 105 with lower scores indicating better outcome
Time frame: 12 weeks
Differences in Fasting Glucose (mmol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in HbA1c (%) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in HbA1c (mmol/mol) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in B-type (ng/L) natriuretic peptide pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in hs-troponin (ng/L) natriuretic peptide pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in CRP (mg/L), natriuretic peptide pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in albumin concentration pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in albumin/creatinine ratio concentration pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in sodium (mmol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in potassium (mmol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in Urea (mmol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in creatinine (umol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in eGFR (ml/min) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in hsTnl(ng/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in hALT (iu/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in ALP (iu/L)pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in LDL (mmol/L) pre- and post intervention
Biochemistry
Time frame: 12 weeks
Differences in kidney function pre- and post intervention
Blood analysis for eGFR (ml/min)
Time frame: 12 weeks
Differences in liver function pre- and post intervention
Blood analysis for ALP (iu/L)
Time frame: 12 weeks
Differences in the levels of physical activity pre- and post intervention
Objectively measured with an accelerometer
Time frame: 12 weeks
Cardiac rehabilitation uptake
The proportion of participants who were offered and attended cardiac rehabilitation following completion of the intervention (%)
Time frame: 12 months
The number of participants who experience any Major Adverse Cardiovascular Events (MACE)
At any point during the study if a participant experiences a major cardiovascular event this will be recorded and reported to sponsor in line with handling serious adverse events
Time frame: 12 weeks